InotivNOTVQ -9.91% PB Ratio is 0.00 as of Jun. 24, 2026. The stock has 4 warning signs investors should review. Among 197 Medical Diagnostics & Research companies, Inotiv ranks better than 99.49% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Inotiv's share price is $0.01. Inotiv's Book Value per Share for the quarter that ended in Mar. 2026 was $2.21. Hence, Inotiv's PB Ratio of today is 0.00.
Good Sign:
Inotiv Inc stock PB Ratio (=0.01) is close to 10-year low of 0.01.
The historical rank and industry rank for Inotiv's PB Ratio or its related term are showing as below:
During the past 13 years, Inotiv's highest PB Ratio was 45.69. The lowest was 0.01. And the median was 1.27.
NOTVQ's PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.02 * Ranked among companies with meaningful PB Ratio only.
During the past 12 months, Inotiv's average Book Value Per Share Growth Rate was -51.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -34.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 30.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Inotiv was 147.30% per year. The lowest was -34.50% per year. And the median was -2.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Inotiv PB Ratio Related Terms
Inotiv PB Ratio Historical Data
* Premium members only.
The historical data trend for Inotiv's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inotiv's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's PB Ratio distribution charts can be found below:
* The bar in red indicates where Inotiv's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Inotiv's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Inotiv (NOTVQ) has a PB Ratio of 0.00 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inotiv and its competitors. Over the past decade, Inotiv's PB Ratio has ranged from 0.01 to 45.69. According to the industry distribution chart, Inotiv ranks #1 out of 197 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Inotiv's PB Ratio too high?
Inotiv's current PB Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 45.69. Based on the distribution chart, Inotiv ranks #1 out of 197 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Inotiv's PB Ratio compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #1 out of 197 companies for PB Ratio. This places Inotiv in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.02. Historically, Inotiv's own PB Ratio has ranged from 0.01 to 45.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 197 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current PB Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current PB Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Inotiv (NOTVQ), the current PB Ratio is 0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 